Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors

被引:53
作者
Al Koudsi, Nael [2 ]
Hoffmann, Ewa B. [2 ,3 ]
Assadzadeh, Abbas [2 ]
Tyndale, Rachel F. [1 ,3 ]
机构
[1] Univ Toronto, Dept Pharmacol & Toxicol & Psychiat, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada
[3] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada
关键词
CYP2A6; Nicotine; Pharmacogenetics; Age; Gender; HUMAN LIVER-MICROSOMES; C-OXIDATION; POLYMORPHIC ALLELES; CYTOCHROME-P450; EXPRESSION; VARIABILITY; METHYLATION; RECEPTOR; SMOKING;
D O I
10.1007/s00228-009-0762-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We investigated the role of genetic, physiological, environmental, and epigenetic factors in regulating CYP2A6 expression and nicotine metabolism. Human livers (n = 67) were genotyped for CYP2A6 alleles and assessed for nicotine metabolism and CYP2A6 expression (mRNA and protein). In addition, a subset of livers (n = 18), human cryopreserved hepatocytes (n = 2), and HepG2 cells were used for DNA methylation analyses. Liver samples with variant CYP2A6 alleles had significantly lower CYP2A6 protein expression, nicotine C-oxidation activity, and affinity for nicotine. Female livers had significantly higher CYP2A6 protein and mRNA expression compared to male livers. Livers exposed to dexamethasone and phenobarbital had higher CYP2A6 expression and activity, however the difference was not statistically significant. Age and DNA methylation status of the CpG island and a regulatory site were not associated with altered CYP2A6. We identified genotype, gender, and exposure to inducers as sources of variation in CYP2A6 expression and activity, but much variation remains to be accounted for.
引用
收藏
页码:239 / 251
页数:13
相关论文
共 43 条
[21]   Drug metabolism and ageing [J].
Kinirons, MT ;
O'Mahony, MS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (05) :540-544
[22]  
Kiyotani Kazuma, 2003, Pharmacogenetics, V13, P689, DOI 10.1097/00008571-200311000-00005
[23]   Transcriptional regulation of human CYP2A13 expression in the respiratory tract by CCAAT/enhancer binding protein and epigenetic modulation [J].
Ling, Guoyu ;
Wei, Yuan ;
Ding, Xinxin .
MOLECULAR PHARMACOLOGY, 2007, 71 (03) :807-816
[24]   ISOLATION AND CHARACTERIZATION OF A CYTOCHROME-P450 OF THE IIA SUBFAMILY FROM HUMAN LIVER-MICROSOMES [J].
MAURICE, M ;
EMILIANI, S ;
DALETBELUCHE, I ;
DERANCOURT, J ;
LANGE, R .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 200 (02) :511-517
[25]  
MEIER PJ, 1983, GASTROENTEROLOGY, V85, P682
[26]  
Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
[27]   Pharmacokinetics of nicotine in healthy elderly people [J].
Molander, L ;
Hansson, A ;
Lunell, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (01) :57-65
[28]   Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of black African descent [J].
Mwenifumbo, Jill C. ;
Al Koudsi, Nael ;
Ho, Man Ki ;
Zhou, Qian ;
Hoffmann, Ewa B. ;
Sellers, Edward M. ;
Tyndale, Rachel F. .
HUMAN MUTATION, 2008, 29 (05) :679-688
[29]  
Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212
[30]   Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations [J].
Nakajima, Miki ;
Fukami, Tatsuki ;
Yamanaka, Hiroyuki ;
Higashi, Eriko ;
Sakai, Haruko ;
Yoshida, Ryoko ;
Kwon, Jun-Tack ;
McLeod, Howard L. ;
Yokoi, Tsuyoshi .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (03) :282-297